SPGL008 with or without BCG for high-risk bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called SPGL008, given alone or with BCG (a standard bladder cancer treatment), for people with high-risk non-muscle invasive bladder cancer who cannot or choose not to have their bladder removed. The study looks at safety and how well the drug works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-risk non-muscle invasive bladder cancer (NMIBC).
- You are not able to or have chosen not to have your bladder removed surgically.
- You are 18 or older and in fairly good health (able to take care of yourself).
- You have good organ function (kidneys, liver, bone marrow working well).
- You do not have other cancers, active infections, or a history of severe side effects from BCG therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a drug (DV) and BCG immunotherapy for people with high-risk, early-stage bladder cancer that has not spread into the muscle. The cancer must show a specific protein called HER2 on its cells.
This trial tests a new combination treatment (SHR-1501 plus BCG) compared to standard chemotherapy for people with bladder cancer that hasn't responded to BCG. The goal is to see if this combination works better at controlling the cancer.
This trial tests a new form of intravesical (given directly into the bladder) treatment called rMBCG for people with non-muscle invasive bladder cancer who have not had BCG therapy before. It may be an option for those with certain types of early bladder cancer, including carcinoma in situ (CIS) or papillary tumors after removal surgery.
This study tests a new drug called UGN-501, given directly into the bladder through a catheter, for people whose bladder cancer (non-muscle invasive) has returned after previous treatments. It aims to find the right dose and see if it helps control the cancer.
This trial tests a new drug (FL115) given directly into the bladder, alone or with BCG, for people with a type of bladder cancer that has not responded to BCG therapy. It aims to find a better treatment option for those who cannot have or refuse bladder removal surgery.
This trial tests whether a new bladder cancer drug (SHR-1501) works alone or combined with BCG, and compares options with another drug (SHR-1316), in people with high-risk non–muscle-invasive bladder cancer. It may help reduce cancer coming back and improve control of the disease.
Hear when a new NMIBC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.